GX Acquisition Corp. II

GX Acquisition Corp. II (Nasdaq: GXII), sponsored by GX Sponsor II LLC, was a blank-check company that completed its initial public offering in 2020 with a focus on the healthcare and biotechnology sector. The SPAC completed its business combination with Celularity Inc., a clinical-stage cell therapy company, in August 2021, with the combined entity subsequently trading on Nasdaq under the ticker CELU. On March 27, 2023, GXII filed a Form 15-12G with the SEC to deregister its class of securities, representing the final administrative step in the SPAC vehicle's wind-down following the completed merger. Sign up on SpacDesk for full filing histories, sponsor profiles, and deal timelines on GXII and thousands of other SPAC transactions.